Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the head and neck cancer (hnc) market grown over the years?

The market size for head and neck cancer (HNC) has been experiencing robust growth in the past few years. The expected progression is an increase from $2.00 billion in 2024 to $2.17 billion in 2025, registering a compound annual growth rate (CAGR) of 8.2%. The substantial growth during the historic period can be linked to the surge in the incidence of HPV-related cancers, a rise in the prevalence of smoking and alcohol use, an upswing in funding for cancer research alongside heightened awareness and early detection, and a demographic shift towards an older population.

What Is the forecasted market size and growth rate for the head and neck cancer (hnc) market?

The market for head and neck cancer (HNC) is anticipated to witness substantial growth in the coming years, reaching a value of $2.93 billion by 2029. This represents a compound annual growth rate (CAGR) of 7.8%. This growth during the forecast period is expected to stem from a variety of factors, such as the improvement of healthcare infrastructure, an increasing number of patients, the growing population of the elderly, rising healthcare costs, and the prevalence of habits like tobacco usage and alcohol consumption. The predicted trend during this period features advancements in immunotherapy, targeted treatments, incorporation of technology, artificial intelligence (AI) integration, and precision medicine.

Get your head and neck cancer (hnc) market report here!

https://www.thebusinessresearchcompany.com/report/head-and-neck-cancer-hnc-global-market-report

What are the major factors driving growth in the head and neck cancer (hnc) market?

The head and neck cancer (HNC) market is expected to surge due to the rise of cigarette smoking cases. Essentially, cigarette smoking is the process of absorbing and releasing smoke from ignited tobacco in cigarettes, which is commonly linked with health issues and dependency. Growth in cigarette smoking is usually spurred by elements such as stress, social influences, assertive marketing, and the easy availability of tobacco products. Drugs for head and neck cancer combat the harmful effects of cigarette smoking by focusing on the molecular alterations caused by smoking and treating cancers associated with tobacco usage. They also stress the importance of minimizing contact with smoking-related carcinogens for improved treatment results. As per a study conducted by the European Respiratory Society (ERS), a Switzerland-based non-profit organization, in October 2024, there was a noticeable surge in smoking rates amongst young people. The report showed that while the smoking rate was 22.5% in 2022, it significantly increased to 40.1% in 2024. Consequently, the escalating incidence of cigarette smoking is propelling the growth of the head and neck cancer (HNC) market.

What key areas define the segmentation of the global head and neck cancer (hnc) Market?

The head and neck cancer (HNC) market covered in this report is segmented –

1) By Type: Laryngeal Cancer, Pharyngeal Cancer, Salivary Gland Cancer, Lip And Oral Cavity Cancer, Nasopharyngeal Cancer, Other Types

2) By Treatment: Chemotherapy, Surgery, Radiation Therapy, Targeted Therapy, Other Treatments

3) By Diagnosis: Bioscopy Screening Tests, Blood Tests, Dental Diagnosis, Imaging, Endoscopy

4) By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, E-commerce

5) By End User: Hospital, Specialty Clinics, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Laryngeal Cancer: Supraglottic Laryngeal Cancer, Glottic Laryngeal Cancer, Subglottic Laryngeal Cancer

2) By Pharyngeal Cancer: Oropharyngeal Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer

3) By Salivary Gland Cancer: Parotid Gland Cancer, Sublingual Gland Cancer, Submandibular Gland Cancer, Minor Salivary Gland Cancer

4) By Lip And Oral Cavity Cancer: Lip Cancer, Buccal Mucosa Cancer, Tongue Cancer, Gingival Cancer, Palate Cancer

5) By Nasopharyngeal Cancer: Early-Stage Nasopharyngeal Cancer, Advanced-Stage Nasopharyngeal Cancer

6) By Other Types: Thyroid Cancer, Esophageal Cancer, Sinonasal Cancer

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20825&type=smp

What are the top market players propelling the growth of the head and neck cancer (hnc) industry?

Major companies operating in the head and neck cancer (HNC) market are Pfizer Inc., Siemens Healthcare Private Limited, F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Bayer Healthcare AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Koninklijke Philips N.V., Boehringer Ingelheim, Fresenius Kabi AG, Incyte Corporation, Exelixis Inc., Astellas Pharma Inc., Rakuten Medical Inc., Merus N.V.

What are the key trends shaping the future of the head and neck cancer (hnc) market?

Major companies operating in the head and neck cancer (HNC) market are focusing on developing innovative formulations such as immune oncology drugs, to enhance treatment efficacy, improve patient survival rates, and address unmet medical needs in managing complex and advanced-stage cancers. Immuno-oncology drugs refer to treatments that harness the body’s immune system to recognize and fight cancer cells. These therapies include checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines. For instance, in November 2024, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, launched toripalimab, an immune oncology drug for adults with a rare form of head and neck cancer that originates in the nasopharynx, the upper part of the throat. This drug is designed for treating recurrent or metastatic nasopharyngeal carcinoma. It will be marketed under the name Zytorvi. The drug has demonstrated a 48% reduction in the risk of progression or death when used in combination with standard chemotherapy (gemcitabine and cisplatin).

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20825

What regions are dominating the head and neck cancer (hnc) market growth?

North America was the largest region in the head and neck cancer (HNC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the head and neck cancer (HNC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Hepatocellular Carcinoma Drugs Global Market Report 2025

https://thebusinessresearchcompany.com/report/hepatocellular-carcinoma-drugs-global-market-report

Unresectable Hepatocellular Carcinoma Global Market Report 2025

https://thebusinessresearchcompany.com/report/unresectable-hepatocellular-carcinoma-global-market-report

Merkel Cell Carcinoma Treatment Global Global Market Report 2025

https://thebusinessresearchcompany.com/report/merkel-cell-carcinoma-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: